Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, ANG Lifesciences India has informed that the Company has received the In-principal Approval vide letter no. LO/Migration/SC/IP/258/2021-22 dated 01-Nov.-2021 for Migration of equity shares of the company from BSE SME Platform to Main Board of BSE. The company enclosed the copy of In principal Approval of the BSE.
The above information is a part of company’s filings submitted to BSE.